BioCryst Pharma (BCRX) Tops Q1 EPS by 7c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $7.65 -1.67%
Revenue Growth %: +3.9%
Financial Fact:
Loss from operations: -9.24M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +3.9%
Financial Fact:
Loss from operations: -9.24M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q1 EPS of $0.00, $0.07 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $134.2 million versus the consensus estimate of $127.91 million.
GUIDANCE:
BioCryst Pharma sees FY2025 revenue of $580-600 million, versus the consensus of $563.6 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kotak Upgrades Indusind Bank Ltd (IIB:IN) to Reduce (3)
- Kotak Upgrades Torrent Pharma (TRP:IN) to Buy (1)
- Indusind Bank Ltd (IIB:IN) PT Lowered to INR875 at Axis Capital Limited
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
